Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00320385 · ClinicalTrials.gov registry record · Phase 3
Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 296
- Enrollment target
NCT00320385 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 296 participants.
The verdict
NCT00320385, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 296 participants
- Enrollment target
Study Summary
This study will evaluate and compare the safety and efficacy of lapatinib in combination with trastuzumab versus lapatinib monotherapy in subjects with HER2-positive metastatic breast cancer.
Interventions
- BIOLOGICAL Trastuzumab
- DRUG Lapatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 296 participants |
| Start Date | 2005-11 |
| Est. Completion | 2010-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00320385
The ClinicalTrials.gov registry entry for NCT00320385 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 296 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Trastuzumab is the first listed.
NCT00320385 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00320385 about?
NCT00320385 is a clinical study titled "Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer". This study will evaluate and compare the safety and efficacy of lapatinib in combination with trastuzumab versus lapatinib monotherapy in subjects with HER2-positive metastatic breast cancer.
What is the current status of trial NCT00320385?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 296 participants. The study started on 2005-11. Estimated completion is 2010-10.
What interventions are being tested in trial NCT00320385?
The interventions under investigation include: Trastuzumab (BIOLOGICAL), Lapatinib (DRUG).
Who is sponsoring clinical trial NCT00320385?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.